SHANGHAI, May 21 (Reuters) - Eli Lilly ( LLY ) said on
Tuesday its tirzepatide drug has received approval from Chinese
regulators for use to treat type 2 diabetes.
Tirzepatide is the active ingredient in the U.S. firm's
diabetes drug Mounjaro and weight-loss drug Zepbound.
(Reporting by Andrew Silver; Editing by Muralikumar
Anantharaman)